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Abstract 49 
IMPORTANCE 50 
There is a trend towards treating conjunctival lesions suspected to be ocular surface 51 
squamous neoplasia (OSSN) based on the clinical impression. 52 
 53 
OBJECTIVES 54 
To describe the presentation of OSSN and identify clinical features which distinguish it from 55 
benign lesions and subsequently evaluate their recognisability. 56 
 57 
DESIGN, SETTING AND PARTICIPANTS 58 
Prospective multi-centre study in Kenya from July 2012 through July 2014 of 496 adults 59 
presenting with conjunctival lesions.  60 
 61 
EXPOSURES 62 
Comprehensive history, slit lamp examination and photography before excision biopsy. 63 
Frequency of clinical features in OSSN and benign lesions recorded. One histopathologist 64 
examined all specimens. Six additional masked ophthalmologists independently examined 65 
photographs from 100 participants and assessed clinical features. 66 
 67 
MAIN OUTCOMES AND MEASURES 68 
Proportions and means were compared using Chi-square, Fisher’s exact test or t-test as 69 
appropriate. Inter-observer agreement was estimated using Kappa statistic. Examiners’ 70 
assessments were compared to a reference. 71 
 72 
RESULTS 73 
Among 496 participants, OSSN was the most common (38%) histological diagnosis, 74 
followed by pterygium (36%) and actinic keratosis (19%). OSSN cases were slightly older 75 
and tended to have lower levels of education than benign ones. Females predominated 76 
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(67% of OSSN vs 64% of benign lesions; P = .65). HIV-infection was common among OSSN 77 
cases (74%). The commonest location was the nasal limbus (61% OSSN vs 78% benign 78 
lesions; P < .001). Signs more frequent in OSSN included; feeder vessels, odds ratio [OR], 79 
5.8 [95%CI, 3.2-10.5]; moderate inflammation, OR, 3.5 [95%CI,1.8-6.8]; corneal 80 
involvement, OR, 2.7 [95%CI,1.8-4.0]; leukoplakia, OR, 2.6 [95%CI,1.7-3.9]; papilliform 81 
surface, OR, 2.1 [95%CI,1.3-3.5]; pigmentation, OR, 1.5 [95%CI, 1.0-2.2]; temporal location, 82 
OR, 2.0 [95%cI, 1.2-3.2]; circumlimbal location, (7.0% vs 0.3%; P<.001); severe 83 
inflammation (6.0% vs 0.3%; P <.001) and larger mean [SD] diameter (6.8 [3.2]mm vs 84 
4.8[2.8]mm; P < .001). All OSSN signs were also observed in benign lesions. There was 85 
slight to fair inter-observer agreement in assessment of most signs and diagnosis (Kappa, 86 
0.1-0.4). The positive predictive value of clinical appearance in identifying OSSN was 54% 87 
(interquartile range, 51-56) from photographs where prevalence was 32%.    88 
 89 
CONCLUSIONS AND RELEVANCE 90 
With overlapping phenotypes and modest inter-observer agreement, OSSN and benign 91 
conjunctival lesions are not reliably distinguished clinically. Point-of-care diagnostic tools 92 
may help. 93 
 94 
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Background 95 
Ocular surface squamous neoplasia (OSSN) is a spectrum of pathology ranging from non-96 
invasive intra-epithelial dysplasia of the conjunctiva and cornea (CCIN) to invasive 97 
squamous cell carcinoma.1 Worldwide, the incidence rate of OSSN is highest in the southern 98 
hemisphere (160S) with the peak occurring in Africa.2  99 
 100 
The gold standard for diagnosis of OSSN is histopathology; however, the availability of this 101 
service is limited in Africa.3, 4 The decision to excise conjunctival lesions usually depends on 102 
the clinical impression. Most lesions are excised without subsequent histopathological 103 
confirmation of the diagnosis or information on tumour involvement of the excision margins. 104 
Even in countries with good access to pathology services, many lesions suspected of being 105 
OSSN are treated without histological confirmation of the diagnosis. In 2003 a standard of 106 
care survey in the USA showed that 51% of respondents always perform biopsies before 107 
instituting therapy for suspected OSSN lesions.5 This proportion was unchanged when the 108 
same survey was repeated in 2012.6 There are several reports from other regions where 109 
primary treatment for suspected OSSN tumours is provided using topical agents (mitomycin 110 
C, 5-fluorouracil, and interferon α2b) without excision for histopathological diagnosis.7-10 The 111 
rationale for this practice is to reduce the complications of excision such as limbal stem cell 112 
deficiency with large lesions or symblepharon. Population surveys to determine the 113 
prevalence of pinguecula or pterygium also rely on a clinical diagnosis to distinguish them 114 
from OSSN and other benign lesions.11-13  115 
 116 
Several studies have tried to identify clinical features that may distinguish OSSN. A study in 117 
Tanzania found that OSSN lesions had a shorter mean duration than benign lesions (3.7 118 
months vs 8.8 months; P = .03) while feeder vessels were more frequently associated with 119 
OSSN than benign lesions (P = .03).14 Male gender, temporal and superior locations, lack of 120 
corneal involvement, papillomatous and nodular appearance were associated with higher-121 
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grade OSSN lesions in a US study.15 OSSN lesions in HIV-infected individuals may be more 122 
likely to be of a higher grade of malignancy than HIV-negative patients.16  123 
 124 
The aim of this study was to describe the clinical presentation of OSSN in Kenya and 125 
determine what clinical features might help to distinguish it from benign lesions. The main 126 
focus was on the frequency of clinical features in OSSN that could help to differentiate 127 
OSSN from other benign conjunctival lesions in this setting and the inter-observer variability 128 
in the recognition of these features.  129 
 130 
 131 
Methods 132 
Ethical Approval 133 
This study was part of an integrated set of investigations into OSSN in Kenya. It was formally 134 
reviewed and approved by the Kenyatta National Hospital – University of Nairobi Ethics and 135 
Research Committee and the London School of Hygiene and Tropical Medicine Ethics 136 
Committee. This study adhered to the tenets of the Declaration of Helsinki. All participants 137 
gave informed written consent to take part in the study before enrolment and did not receive 138 
a stipend to participate.  139 
 140 
Participants 141 
Recruitment was between July 2012 and July 2014 in four eye care centers: Kenyatta 142 
National Hospital in Nairobi, PCEA Kikuyu Eye Unit about 25 kilometres (km) from Nairobi in 143 
Central Kenya, Kitale district hospital in the north Rift Valley 490km from Nairobi and Sabatia 144 
Eye Hospital 300km from Nairobi in the western highlands bordering Lake Victoria. We 145 
prospectively recruited all consenting, consecutive self-presenting adult patients (at least 18 146 
years of age) with any conjunctival lesion (first presentation or a recurrence) suspected to be 147 
OSSN scheduled for surgery. Pregnant women and breastfeeding mothers were excluded. 148 
 149 
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Clinical Assessment 150 
A comprehensive history was taken using a structured questionnaire and the eyes were 151 
examined with a slit lamp. The widest diameter of the lesion was measured using the slit 152 
lamp beam and scale. A pair of photographs of each lesion was taken, one in primary gaze 153 
and the other with the lesion in the center of the field. We used a Nikon D90 digital camera 154 
with Micro Nikkor 105mm F2.8 AFS zoom lens and the R1 close up speedlight. All photos 155 
were taken at 1:1 magnification ratio.  156 
 157 
Surgery and Histopathology 158 
All lesions were excised under local anaesthetic using an operating microscope with a 3mm 159 
clear margin. Cryotherapy was not applied as the participants were further invited to enroll in 160 
a treatment trial post-operatively. Specimens were placed directly into buffered formalin and 161 
subsequently examined at the histopathology laboratory at the MP Shah Hospital, Nairobi. 162 
One pathologist examined all the histology slides. Participants with mild, moderate or severe 163 
conjunctival intraepithelial neoplasia (CIN I, II, III respectively) together with any who had 164 
carcinoma-in-situ (CIS) and invasive squamous cell carcinoma were classified as having 165 
OSSN. A three-grade system was used to classify carcinomas histologically as well, 166 
moderately and poorly differentiated after the American Joint Committee on Cancer 167 
(AJCC).17 Benign lesions included pterygium, actinic keratosis, papillomas, pyogenic 168 
granulomas, nevi and rhinosporidiosis. The diagnosis of actinic keratosis was based on the 169 
presence of elastotic stromal degeneration, acanthosis, hyperkeratosis and parakeratosis in 170 
the presence of normal cellular polarity. By the accepted criteria for dysplasia, such lesions 171 
were classified as CIN only if there is loss of polarity. 172 
 173 
 174 
Cases of OSSN were invited to enroll in a case-control study that involved testing for HIV 175 
and CD4 count. HIV was initially tested using Vironostika antigen/antibody kit then later 176 
changed to rapid tests using Alere Determine HIV-1/2 Ag/Ab and Trinity Unigold. CD4 count 177 
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was tested using FacsCount (Becton Dickinson) USA. Those with benign lesions were not 178 
tested. Voluntary testing and counselling was offered at the health facility. 179 
 180 
Inter-observer Study 181 
To determine the inter-observer variability in the assessment of the clinical features six final 182 
year ophthalmology residents in the University Of Nairobi Department Of Ophthalmology at 183 
Kenyatta National Hospital independently assessed photographs from the last 100 184 
consecutive participants enrolled into the study from one center. They were masked to the 185 
diagnosis. Images were projected onto a screen. The clinical case-mix was the same in this 186 
sample of patients compared to the whole dataset that included patients from all the four 187 
study centers. Cases with features that may suggest malignancy such as very large tumours 188 
filling the orbit were excluded from this assessment. The graders were asked to determine if 189 
each feature was either present, absent or difficult to determine.  190 
 191 
Statistical Analysis 192 
Data was managed in an Access database (Microsoft), cleaned and transferred into STATA 193 
version 12.1 (StataCorp, College Station, Texas, USA) for analysis. In this analysis we 194 
compared the clinical features of OSSN and benign lesions. Large orbital tumours and non-195 
OSSN malignancies were excluded. Categorical variables were compared using the 196 
Pearson’s chi-square test, odds ratios (ORs) or Fisher’s exact test where appropriate. 197 
Logistic regression was used to obtain adjusted ORs. To determine whether continuous 198 
variables were normally distributed we generated Q-Q plots and compared the variances in 199 
both groups using the standard deviation test. Where the deviations differed the t-test was 200 
conducted with unequal variances. 201 
 202 
The inter-observer agreement between graders was compared using the kappa (Κ) statistic 203 
without weighting and graded using the Landis & Koch method as poor, slight, fair, 204 
moderate, substantial or almost perfect.18 To calculate an average value, the kappa statistics 205 
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for each grader were transformed to Z scores using the Fisher Z transformation, averaged, 206 
and then back-transformed to kappa.     207 
 208 
 209 
Results 210 
Five hundred and thirty-seven participants with conjunctival lesions were enrolled. Histology 211 
reports were available for 496 participants. Eighteen tissue specimens were autolysed on 212 
arrival at the pathology lab perhaps from poorly reconstituted formalin (one was a batch of 213 
16 from one center) and 22 were presumed lost in transit. Seven (1.4%) were large orbital 214 
tumours. A total of 488 participants were therefore included in the analysis of clinical 215 
features.  216 
 217 
Histopathological Diagnosis 218 
OSSN was the most common type of ocular surface lesion (38%) (eTable 1 in the 219 
supplement). This was followed by pterygium (36%) and actinic keratosis (19%), which were 220 
the most common benign lesions. All stages of OSSN were seen with the most frequent 221 
being moderately differentiated squamous cell carcinoma. There was one case of 222 
sarcomatoid spindle cell carcinoma and a wide range of benign lesions.    223 
 224 
Demographic Characteristics 225 
The demographic characteristics of participants, subdivided by the pathology type are shown 226 
in Table 1. About two-thirds were female (65%), with no difference between OSSN and 227 
benign lesions. Most individuals presenting with conjunctival lesions were young to middle 228 
aged adults (mean [SD] age, 39 [11.3] years). Participants with OSSN were slightly older 229 
than those with benign lesions (P = .002), more likely to be widowed, and to have a lower 230 
level of education. Those who did not have any formal education had the highest risk of 231 
OSSN after adjusting for age and marital status. 232 
 233 
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Clinical History 234 
The primary symptoms at presentation are shown in eTable 2 in the supplement. Overall, the 235 
presenting symptoms were similar by disease group (P = .14). The most frequent presenting 236 
complaint was a lump or swelling (67%) followed pain (12%), redness (6%) and itchiness 237 
(5%).  238 
 239 
Additional information on the clinical history is presented in eTable 3 in the supplement. 240 
Median duration from first developing symptoms to presentation was longer for OSSN than 241 
benign tumours (8 months vs 5 months; P = .03) and a history of prior conjunctival excision 242 
was more frequent in OSSN than benign lesions (18% vs 6%; P < .001). The mean [SD] 243 
number of prior excision surgeries where this had taken place was however similar in both 244 
groups (1.4 [0.8] vs 1.3 [0.7]; P = .66). There was no evidence of a difference between 245 
OSSN and benign lesions in terms of a family history of eye cancer or cancer at another site.  246 
 247 
There was strong evidence that participants with OSSN had longer sun exposure in their 248 
current (P = .02) and previous (P = .003) occupation, but little evidence that they had a 249 
current predominantly outdoor occupation (64% vs 57%; P = .14), or worked outdoors in 250 
previous employment (57% vs 48%; P = .22). There was no difference in the proportion who 251 
wore hats or sunglasses, or who smoked cigarettes. However, among smokers, the mean 252 
[SD] number of cigarettes smoked daily was higher among OSSN patients (12 [11] vs 7[6], P 253 
= .03). 254 
 255 
Of 133 OSSN patients tested for HIV, 98 (74%) were positive. Median CD4 count of 91 256 
patients with OSSN was 265 cells/mm3 (interquartile range, 125-670 cells/mm3). Some 257 
participants did not return for histology results after surgery and thus were not tested for HIV 258 
or CD4. Participants with OSSN were more likely to be on ART than those with benign 259 
lesions (38% vs 15%; P < .001). There was little evidence of a difference (P = .30) in mean 260 
[SD] duration of ART use in those with OSSN (2.9 [3.0] years) compared to those with 261 
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benign lesions (3.5[2.9] years). According to the Kenya Ministry of Health HIV guidelines, 262 
HIV-infected patients with CD4≤350 cells/mm3 at first contact would be eligible for ART.19 It 263 
is difficult to know how many of our patients were eligible for ART as they were already in 264 
various stages of HIV care.  265 
 266 
Clinical Features 267 
Clinical features are described in Table 2 and illustrated in Figures 1&2. There were a wide 268 
variety of presentation patterns for each type of OSSN. We illustrate this with a range of 269 
moderately differentiated squamous cell carcinoma tumours in Figure 1, F-O. Overall, OSSN 270 
lesions were larger than benign lesions (mean [SD] diameter 6.8 [3.2] mm vs 4.8mm [2.8], P 271 
< .001). All the features seen in OSSN also occurred in benign lesions (Table 2) and this 272 
overlap is illustrated in Figure 2. OSSN lesions were more likely to be at the temporal limbus 273 
(28% vs 16%; P = .002), circumlimbal (7.0% vs 0.3%; P < .001), to have severe 274 
inflammation (P < .001) and leukoplakia (72% vs 50%; P < .001). A gelatinous appearance 275 
occurred with almost equal frequency in both groups, while a fibrovascular appearance was 276 
more frequent in benign lesions and a papilliform appearance in OSSN. OSSN was more 277 
likely to be pigmented, have a feeder vessel and involve the cornea. Regional 278 
lymphadenopathy was rare (n=7, 1.5%) in OSSN even in those with large orbital tumours.  279 
 280 
Patients with large orbital tumours 281 
All seven participants with large orbital tumours had squamous cell carcinoma. Four were 282 
female and 3 were male. Their age ranged from 30 to 85 years. Only one had prior excision 283 
surgery, although no histology report was available. The tumours had been first noted 7 284 
months to 15 years earlier. Five had HIV infection and 3 were on ART. Despite having large 285 
tumours for a long time only 2 of them had regional lymphadenopathy.  286 
 287 
Inter-observer variation in recognition of clinical features 288 
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Inter-observer variation is described in eTable 4 in the supplement. Overall there was fair to 289 
moderate agreement in assessment of most signs and the clinical diagnosis. Most features 290 
were easily recognized by the graders. The proportions of features they recognized were 291 
fairly similar to an experienced examiner. Using clinical features to make a diagnosis of 292 
OSSN had a median sensitivity of 86% (interquartile range, 81-88), specificity of 60% 293 
(interquartile range, 53-69) and positive predictive value of 54% (interquartile range, 51-56) 294 
among the six examiners (eTable 5 in the supplement).  295 
 296 
 297 
Discussion 298 
There appears to be a tendency to treat presumed OSSN without a tissue diagnosis. 299 
However, we found a high degree of overlap in the clinical features of OSSN and benign 300 
lesions. Although some features were more frequent in OSSN than the benign group, they 301 
still occurred at a fairly high frequency in the benign group. In our view, the differences are 302 
insufficient to depend upon clinical features as an indicator of the underlying diagnosis. 303 
Moreover, there was only modest (k=0.4) inter-observer agreement in the assessment of the 304 
diagnosis and a positive predictive value (54%) no better than chance when using clinical 305 
features to make the diagnosis. The difficulty observed in determining surface appearance 306 
may be partly attributed to the lack of a stereoscopic view from photographs. The agreement 307 
in determining the presence of most clinical features was better than that for overall 308 
diagnostic classification into OSSN or benign.  309 
 310 
The age and sex distribution of OSSN patients was consistent with prior series from Africa, 311 
where young adults and especially women predominate.2, 20 In temperate regions it is 312 
predominantly a disease of older males.21, 22 There was no difference in the sex distribution 313 
of OSSN and benign lesions. Higher education may increase awareness and earlier health 314 
seeking behaviour. Median duration before presentation did not however conform to this 315 
trend, and possibly showed the opposite of what has been previously reported.  316 
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 317 
The medical history of patients with OSSN and benign lesions is essentially similar. The 318 
difference in occupational history with a longer exposure to solar ultraviolet radiation (UVR) 319 
in those with OSSN than benign lesions is consistent with UVR being a major risk factor for 320 
OSSN.2 There was also a heavier exposure to cigarette smoking with OSSN lesions, which 321 
has so far not been clearly described as a risk factor for OSSN.  322 
 323 
Although some clinical features showed differences between OSSN and benign lesions, it 324 
may be difficult to tell the two apart. For instance, OSSN lesions were larger than benign 325 
lesions but a 2.0mm difference between 6.8mm and 4.8mm is relatively small. A 326 
circumlimbal pattern was more frequent in OSSN; however, it only occurred in 3% of the 327 
conjunctival lesions. While OSSN was twice as likely to be temporal, 16% of benign lesions 328 
were located temporally, compared to 28% of OSSN lesions. Such a difference in proportion 329 
is difficult to rely on in the clinical setting. 330 
 331 
The preponderance of nasal conjunctival lesions is consistent with earlier reports, and may 332 
be due to the previously described observation that incident temporal sunlight is focused 333 
nasally with a 20-fold magnification in intensity.23 Pterygia and actinic keratosis are 334 
considered pre-malignant and have some similarities with OSSN in their pathophysiology 335 
including association with solar UV radiation, p53 gene mutation and human papilloma virus 336 
(HPV).24-27 Being on the same causal pathway may also explain the overlap of clinical 337 
features. Further, we would also expect benign changes to occur before malignant ones. 338 
This may explain why OSSN cases were older than the benign cases most of whom had 339 
pterygia or actinic keratosis.  340 
 341 
Differences between OSSN and benign lesions in the proportions of moderate and severe 342 
inflammation (P <.001) may not in isolation be easily applied in the clinical setting. OSSN 343 
was more likely to show leukoplakia than benign lesions , however 50% of benign lesions 344 
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also had it.  This situation is also seen with other features like the lesion surface 345 
appearance, pigmentation, feeder vessels and corneal involvement in Table 2 & Figure 2.  346 
 347 
This study has a number of limitations. The six examiners in the inter-observer component 348 
did not have a full history, which may help to inform the clinical diagnosis, nor did they 349 
assess the lesions at the slit lamp as this would have been logistically impossible. Secondly, 350 
this was a hospital-based study, which may introduce selection bias in the types of patients 351 
seen. However the objective of the study was to compare OSSN and benign lesions 352 
presenting to clinicians in a healthcare facility setting, so this potential bias would not affect 353 
comparability of the two types of disease. Finally, distinguishing pterygia and OSSN by 354 
histopathology is sometimes difficult. Studies in Australia and USA found histopathological 355 
features of OSSN in 9.8% and 1.7% respectively of lesions previously classified as 356 
pterygia.28, 29  357 
 358 
In conclusion the clinical features of OSSN and benign conjunctival lesions overlap. Both 359 
disease groups have common pathophysiological mechanisms and this may explain their 360 
overlapping clinical appearance. Although individual features are identified by different 361 
examiners with reasonable consistency, they do not reliably distinguish the two disease 362 
groups. Examination of photographs alone cannot replace clinical examination and biopsy, 363 
indicating that teleophthalmology approaches for the diagnosis of OSSN require more study. 364 
Therefore in the African context where the range of risk factors is perhaps wider and the 365 
clinical behaviour of the disease more aggressive compared to temperate regions we 366 
conclude that biopsy should be performed before treatment. The occurrence of malignant 367 
changes described in pterygia and other benign lesions further underscores the need for 368 
histopathology.  369 
 370 
 371 
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Figure titles and legends 466 
Figure 1. Five grades of inflammation associated with OSSN are shown in A-E. Various clinical 467 
features seen in moderately differentiated squamous cell carcinoma are shown from F to O. F-468 
K shows different tumour surface appearances and various growth patterns are seen in L-O.  469 
(A) No inflammation; (B) Minimal inflammation with leukoplakia and brown pigmentation;n (C) Mild 470 
inflammation with leukoplakia; (D) Moderate inflammation with leukoplakia; (E) Severe inflammation 471 
with leukoplakia; (F) Leukoplakia – patches of keratosis visible as white adherent plaques. Feeder 472 
vessels (distinctly dilated blood vessels larger than the rest of conjunctival vessels) are also shown by 473 
yellow arrows; (G) Erythoplakia – a red subconjunctival popular haemorrhage-like appearance; (H) 474 
Gelatinous appearance; (I) Fibrovascular appearance; (J) Papilliform appearance with markedly large 475 
feeder vessels (yellow arrows); (K) Brown pigmentation; (L) circumlimbal lesion; (M) pedunculated 476 
lesion;(N) Extensive corneal involvement with orbital disease; (O) Symblepharon. 477 
 478 
 479 
Figure 2. Overlapping clinical features of OSSN and benign/pre-malignant lesions.  480 
A gelatinous surface with pigmentation in (A) a moderately differentiated squamous cell carcinoma 481 
and (B) a pterygium. A papilliform surface in (C) CIN2 and (D) a squamous papilloma. Note that the 482 
squamous papilloma in addition shows multiple feeder vessels. A fibrovascular appearance in (E) a 483 
moderately differentiated squamous cell carcinoma and (F) a pterygium. The pterygium has some 484 
brown pigmentation also seen on the temporal side of the same eye. Leukoplakia with moderate 485 
inflammation in (G) a well differentiated squamous cell carcinoma and (H) an actinic keratosis 486 
showing. Brown pigmentation in (I) CIN3 and (J) a nevus.  487 
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Table 1. Demographic characteristics of participants with OSSN and benign conjunctival lesions. This includes orbital disease. 488 
 489 
Demographic feature OSSN Benign OSSN vs Benign lesions
 N=187 N=308 Crude OR (95% CI) P value Adj ORa (95% CI) P value
Sex, No. (%)     
  Male 62 (33.0) 110 (36.0) 1 [Reference]  1 [Reference]  
  Female 125 (67.0) 198 (64.0) 1.1 (0.8 - 1.6) .56 1.1 (0.8 - 1.6) .65 
Age in years, mean (SD), y 41 (11.6) 38 (10.9) NA .002b NA NA 
Marital status, No. (%)     
  Single 30 (16.0) 42 (14.0) 1 [Reference]  1 [Reference]  
  Married 123 (66.0) 231 (75.0) 0.8 (0.4 - 1.3) .04 0.5(0.3 - 0.9) .05 
  Divorced or Separated 11 (6.0) 18 (6.0) 0.9 (0.4 - 2.1)  0.5 (0.2 - 1.3)  
  Widowed 23 (12.0) 17 (6.0) 1.9 (0.9 - 4.2)  0.9 (0.4 - 2.2)  
Highest education level, No. (%)     
  More than secondary 17 (9.0) 66 (21.0) 1 [Reference]  1 [Reference]  
  Completed secondary school 58 (31.0) 85 (28.0) 2.7(1.4 - 5.0)  2.7 (1.4 - 5.1)  
  Some secondary school 13  (7.0) 37 (12.0) 1.4 (0.6 - 3.1) .001 1.4 (0.6 - 3.4) <.001 
  Completed primary school 57 (30.0) 74 (24.0) 3.0 (1.6 - 5.8)  3.1 (1.6 - 5.9)  
  Some primary school 24 (13.0) 38 (12.0) 2.5 (1.2 - 5.2)  2.4 (1.1 - 5.3)  
  None 18 (10.0) 8 (3.0) 8.7 (2.9 - 26.5)  10.8 (3.3 - 34.8)  
Abbreviations: OSSN, ocular surface squamous neoplasia; SD, standard deviation; NA, not applicable 490 
a adjusted for education, age group and marital status. Sex did not change the multivariable model so it was not included.  491 
b t test  492 
 493 
 494 
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Table 2. Comparison of the clinical features of OSSN with benign conjunctival lesions on slit 495 
lamp examination. 496 
 497 
Clinical feature OSSN Benign lesions OSSN vs benign 
 N=180 N=308  
 No. (%) No. (%) OR (95% CI) P value
Lesion location  
  nasal limbus  110 (61.0) 241 (78.0) 0.4 (0.3 - 0.7) <.001
  temporal limbus  50 (28.0) 50 (16.0) 2.0 (1.2 - 3.2) .002
  superior limbus 2 (1.0) 2 (0.7) 1.7 (0.1 - 23.9) .59
  inferior limbus 1 (0.6) 4 (1.3) 0.4 (0.0 - 4.3) .43
  circumlimbal  12 (7.0) 1 (0.3) 21.9 (3.2 - 940.2) <.001
  mostly corneal  1 (0.6) 0 (0.0) ∞ .19
  both nasal & temporal limbus 3 (2.0) 1 (0.3) 5.2 (0.4 - 274.0) .11
  caruncle  0 (0.0) 3 (1.0) 0 (0.0 - 2.2) .18
  lid  1 (0.6) 6 (2.0) 0.3 (0.0 - 2.4) .21
Inflammation at the lesion site  
  none 21 (13.0) 74 (24.0) 1[Reference] 
  minimal 50 (28.0) 111 (36.0) 1.6 (0.9 - 2.9) 
  mild 46 (25.0) 71 (23.0) 2.3 (1.2 - 4.3) <.001
  moderate 51 (28.0) 51 (17.0) 3.5 (1.8 - 6.8) 
  severe 12 (6.0) 1 (0.3) 42.3 (3.7 - 478.3) 
Leukoplakia 129 (72.0) 152 (50.0) 2.6 (1.7 - 3.9) <.001
Erythroplakia 30 (17.0) 53 (17.0) 1.0 (0.6 - 1.6) .88
Gelatinous appearance 121 (67.0) 188 (61.0) 1.3 (0.9 - 2.0) .19
Fibrovascular appearance 18 (10.0) 81 (26.0) 0.3 (0.2 - 0.6) <.001
Papilliform appearance 41 (23.0) 38 (12.0) 2.1 (1.3 - 3.5) .003
Brown lesion pigmentation  96 (53.0) 133 (44.0) 1.5 (1.0 - 2.2) .04
Lesion feeder vessels 163 (91.0) 195 (64.0) 5.8 (3.2 - 10.5) <.001
Corneal involvement 115 (65.0) 121 (40.0) 2.7 (1.8 - 4.0) <.001
Lesion diameter, mean (SD), mm 6.8 (3.2) 4.8 (2.8) NA <.001 b
Abbreviations: OSSN, ocular surface squamous neoplasia; SD, standard deviation; NA, not applicable; ∞ stands for infinite 498 
a The numbers assessed may vary in different cells if the item assessed did not apply to all participants 499 
b t-test 500 
 501 


